고분자 원료의약품 CDMO 시장 규모, 점유율, 성장 분석 : 서비스별, 원료원별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Large Molecule Drug Substance CDMO Market size was valued at USD 12.88 Billion in 2024 and is poised to grow from USD 13.99 Billion in 2025 to USD 27.06 Billion by 2033, growing at a CAGR of 8.6% during the forecast period (2026-2033).

The global market for large molecule drug substance CDMOs is driven by the rising approvals of biologics, escalating incidences of infectious diseases, and an increasing demand for novel therapeutics. As pharmaceutical and biotech companies invest more in advanced technologies and collaboration with CDMOs, the need for high-quality, CGMP-compliant manufacturing services has surged, particularly highlighted during the pandemic. The urgency for effective vaccines and monoclonal antibodies has showcased the critical role of CDMOs in drug substance (DS) and drug product (DP) development, emphasizing the importance of regional partnerships within the pharmaceutical ecosystem. Despite challenges in affordability and efficiency due to the complexity of large molecules, innovative techniques like encapsulation are emerging to enhance stability and efficacy, positioning CDMOs as essential players in the drug development landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Large Molecule Drug Substance CDMO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Large Molecule Drug Substance CDMO Market Segments Analysis

Global Large Molecule Drug Substance CDMO Market is segmented by Service, Source, End-user and region. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Source, the market is segmented into Mammalian, Microbial and Others. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Large Molecule Drug Substance CDMO Market

The demand for large molecule drug substance contract development and manufacturing organizations (CDMOs) has significantly increased due to substantial investments made by companies in the development of biologics and biosimilars. A large portion of potential therapeutic candidates currently in the discovery phase consists of biologics, including peptides, proteins, and monoclonal antibodies. This surge in investment in research and development by biopharmaceutical firms has led to a growing number of innovative biologics being developed and advanced through the pipeline. As a result, these factors collectively drive the expansion of the CDMO market for large molecule drugs.

Restraints in the Global Large Molecule Drug Substance CDMO Market

The Global Large Molecule Drug Substance CDMO market faces significant challenges due to the inherent complexity associated with characterizing large molecules. In the biopharmaceutical sector, thorough characterization is essential for assessing vital parameters such as stability, purity, and function. Achieving effective structural validation necessitates the integration of various low- and high-resolution techniques. Moreover, the recombinant synthesis process often leads to various post-translational modifications (PTMs) in large molecules, complicating their characterization further. Despite these hurdles, the market is supported by increasing investments in research and development as well as product innovation, which continue to drive advancements in the field.

Market Trends of the Global Large Molecule Drug Substance CDMO Market

The Global Large Molecule Drug Substance CDMO market is undergoing a transformative shift driven by the rising demand for biopharmaceuticals and the complexities of their production. Unlike traditional small-molecule drugs, large biologics require specialized manufacturing that often involves smaller batch sizes and unique formulations, particularly in oncology and personalized medicine. This environment has spurred the growth of innovative startups that lack the resources for in-house manufacturing, emphasizing the need for agile contract development and manufacturing organizations (CDMOs) to offer tailored solutions. As regulatory standards tighten, these CDMOs must enhance containment methods and adapt operational strategies to meet the demands of high-potency active pharmaceutical ingredients (APIs), solidifying their role in a market characterized by rapid advancements and increasing complexity.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Large Molecule Drug Substance CDMO Market Size by Service & CAGR (2026-2033)

• Market Overview
• Contract Manufacturing
  • Clinical
  • Commercial
• Contract Development
  • Cell Line Development
  • Process Development

Global Large Molecule Drug Substance CDMO Market Size by Source & CAGR (2026-2033)

• Market Overview
• Mammalian
• Microbial
• Others

Global Large Molecule Drug Substance CDMO Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Biotech Companies
• CRO
• Others

Global Large Molecule Drug Substance CDMO Market Size & CAGR (2026-2033)

• North America (Service, Source, End-user)
  • US
  • Canada
• Europe (Service, Source, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service, Source, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service, Source, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service, Source, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avid Bioservices (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim BioXcellence (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rentschler Biopharma SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI Biopharma (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JHL Biotech (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVectra (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations